Biostem Technologies

Biostem Technologies Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Biostem Technologies (BSEM) as of Nov 19, 2026 is 76.77 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 41.25 % — a change of 86.12% (higher).

Cash Conversion

76.77 %

YoY

86.12%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Biostem Technologies is 2024 76.77 % . Cash Conversion Rate (OCF/Net Income) of Biostem Technologies was 2023 41.25 % . It decreases by 86.12% higher compared to the previous year.

The Biostem Technologies Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2017
34.01 USD
Jan 1, 2018
48.20 USD
Jan 1, 2019
13.35 USD
Jan 1, 2020
24.34 USD
Jan 1, 2021
7.57 USD
Jan 1, 2022
23.14 USD
Jan 1, 2023
41.25 USD
Jan 1, 2024
76.77 USD
The Biostem Technologies Cash Conversion history
YEARCash ConversionYoY
76.77 %+86.12%
41.25 %+78.27%
23.14 %+205.58%
7.57 %-68.89%
24.34 %+82.32%
13.35 %-72.30%
48.20 %+41.72%
34.01 %-20.55%
42.81 %+188.19%
14.85 %-85.09%
99.65 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biostem Technologies Stock analysis

What does Biostem Technologies do? Biostem Technologies Inc is a US company specializing in regenerative medicine. It was founded in 2007 and is based in Clearwater, Florida. Biostem Technologies is listed on the OTCQB Stock Exchange and offers a wide range of products in the field of regenerative medicine. The company's business model primarily involves advancing growth in the field of regenerative medicine through the development and marketing of new products and technologies. They focus on the production of stem cells that can be used in the regeneration of damaged tissues and organs. They also offer research and development of stem cell therapies, manufacturing of stem cell products, and related services. Biostem Technologies places emphasis on processing umbilical cord blood stem cells, collaborating with medical facilities to collect and isolate these cells for preservation. The company has also developed products such as BioStem Serum and BioStem Gel, made from stem cells and used in regeneration and wound healing. They have developed technologies for regenerating damaged tissues and organs, including a technology for regenerating muscle and adipose tissue through stem cell injection. Clinical studies have shown promising results with this technology. Biostem Technologies has partnerships with other companies and institutes in the field of regenerative medicine, including working with the National Institute of Neurological Disorders and Stroke to develop a new therapy for multiple sclerosis. They also provide consulting services to assist other companies in developing regenerative products and services. In conclusion, Biostem Technologies is a leading company in the field of regenerative medicine and stem cell therapies, offering a range of products and services. They also provide important technologies for tissue regeneration, positioning them as a key player in the field of regenerative medicine. Biostem Technologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biostem Technologies stock

Cash Conversion Rate (OCF/Net Income) of Biostem Technologies is 76.77 % in 2024.

Cash Conversion Rate (OCF/Net Income) of Biostem Technologies changed from 41.25 % to 76.77 %, representing a 86.12% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Biostem Technologies since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Biostem Technologies with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Biostem Technologies

All Key Metrics — Biostem Technologies